Current clinical trials use ataxia scores, cerebellar imaging, nerve conductance, perhaps the quantitation of NfL as axonal damage marker, and ATXN2 to assess efficacy of disease protein elimination, but molecular biomarkers in the affected pathways are lacking. This evidence concerns the gene NEFL and cerebellar ataxia.